In 2026, Ironwood Pharmaceuticals expects adjusted EBITDA to exceed $300M, driven by higher LINZESS net sales and disciplined expense management. The company has lowered LINZESS list price to support patient access, anticipating increased sales due to reduced rebates. Strategic review ongoing to maximize shareholder value. Source: TheFly.

Ironwood Pharmaceuticals anticipates FY26 adjusted EBITDA to exceed $300M, with a focus on LINZESS, apraglutide, and profitability. LINZESS list price lowered for patient access, aiming for higher net sales in 2026. Strategic review ongoing to enhance shareholder value. Source: TheFly.

Ironwood Pharmaceuticals projects adjusted EBITDA over $300M for FY26, driven by higher LINZESS sales and cost management. LINZESS list price reduced to support patient access, expecting increased net sales. Strategic review continues for shareholder value. Source: TheFly.

Read more at Yahoo Finance.: Ironwood sees FY26 revenue $450M-$475M, consensus $319.47M